<DOC>
	<DOCNO>NCT01860703</DOCNO>
	<brief_summary>Randomized , single-dose , double-blind , placebo active control , four-period crossover study evaluate effect deferiprone QTc prolongation administration single therapeutic ( 33 mg/kg ) supratherapeutic ( 50 mg/kg ) oral dos deferiprone healthy volunteer compare placebo treatment .</brief_summary>
	<brief_title>Evaluation Whether Deferiprone Affects QT Interval Healthy Subjects</brief_title>
	<detailed_description>Post-marketing study evaluate effect deferiprone deferiprone 3-O-glucuronide QTc prolongation healthy volunteer administration single therapeutic ( 33 mg/kg ) supratherapeutic ( 50 mg/kg ) oral dose deferiprone moxifloxacin ( Avelox® ) .</detailed_description>
	<mesh_term>Deferiprone</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Main 1 . Healthy adult male female , 18 45 year age ( inclusive ) . 2 . Body weight ≥ 50 kg . 3 . Body mass index ( BMI ) ≥ 19 ≤ 32 kg/m2 . 4 . Medically healthy clinically insignificant screen result ( e.g. , laboratory profile , medical history , vital sign , physical examination ) . 5 . Absolute neutrophil count ( ANC ) &gt; 1.5x109/L . 6 . 12lead ECGs clinically significant finding judge Principal Investigator ( PI ) PI 's designee screening checkin study period , include : 1 . Normal sinus rhythm ( heart rate 45 100 bpm ) ; 2 . QTcF interval ≤ 450 msec ; 3 . QRS interval ≤ 110 msec ; 4 . PR interval ≤ 220 msec . 7 . Subject must capable provide write informed consent , must voluntarily consent participate study . 8 . Willing answer inclusion exclusion criterion questionnaire checkin . Main 1 . History presence significant respiratory , cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . 2 . Disorders surgery gastrointestinal tract may interfere drug absorption may otherwise influence PK investigational medicinal product ( e.g . cholecystectomy , resection small large intestine , febrile condition , chronic diarrhea , chronic vomiting , endocrine disease , severe infection , acute inflammation , etc. ) . 3 . Presence liver impairment : aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) normal reference range . 4 . Presence significant kidney impairment : serum creatinine high normal reference range . 5 . Allergy band aid , adhesive dress medical tape . 6 . Clinically significant history presence ECG abnormalities second thirddegree atrioventricular block ; evidence , family history , prolong QT syndrome . 7 . Sustained sit systolic blood pressure &lt; 90 mmHg &gt; 140 mmHg , diastolic blood pressure &gt; 95 mmHg screen checkin Period 1 . 8 . History presence hypersensitivity idiosyncratic reaction deferiprone , moxifloxacin , iron chelators , quinolone antibiotic . 9 . History presence : agranulocytosis ; asthma ; chronic bronchitis ; diabetes ; migraine ; hypertension ; hypotension ; hypokalemia ; seizures epilepsy ; anaemia . 10 . History presence alcoholism drug abuse within past 2 year . 11 . Used tobacco/nicotinecontaining product least 3 month prior first dose study . 12 . Used DepoProvera® levonorgestrel implant within 90 day prior first dose throughout study . 13 . Participation another clinical trial within 28 day prior first dose study . 14 . Had clinically significant illness 4 week prior checkin Day 1 Period 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Ferriprox®</keyword>
	<keyword>LI</keyword>
	<keyword>DFP</keyword>
	<keyword>Deferiprone</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>